Articles liés à Drug Management of Prostate Cancer
Synopsis
Prostate cancer is the most common noncutaneous prostate cancer. Research has revealed several distinct malignancy and the second leading cause of cancer mechanisms of castration-resistant disease that may deaths among men in the United States. It is a critical converge in patients with disease progression on public health problem and remains incurable in the ADT. Many approaches are currently being evaluated metastatic setting with mortality that usually occurs as to improve the treatment of this condition and these a result of castration-resistant disease. fndings have identifed several potential targets for Since Huggins and Hodges' report of the dra- therapeutic intervention. These include drugs that are matic clinical effects of suppressing serum testos- more active or less toxic chemotherapy agents; drugs terone levels in men with advanced prostate cancer that induce androgen deprivation; drugs that target in 1941, hormone therapy (also called androgen the androgen receptor and/or androgen synthesis; deprivation therapy [ADT]) has become widely drugs that target specifc pathways, including ang- accepted as the mainstay of therapy for the treat- genesis and tyrosine kinase inhibitors, endothelin ment of advanced prostate cancer. ADT combined antagonists and matrix metalloproteinase inhibitors; with radiation therapy is a standard of care in the and immunologic approaches. Many of these agents treatment of men with locally advanced prostate seem promising and the rationale and effcacy of cancer on the basis of evidence that shows improved these emerging therapies remain to be validated in survival. The role of ADT in the management of future clinical trials.
Les informations fournies dans la section « Synopsis » peuvent faire référence à une autre édition de ce titre.
Acheter neuf
Afficher cet article
EUR 82,74
Gratuit expédition vers Etats-Unis
Destinations, frais et délais
Résultats de recherche pour Drug Management of Prostate Cancer
Image d'archives
Drug Management of Prostate Cancer.
Edité par
Springer, New York, 2010
ISBN 10 : 1603278311
ISBN 13 : 9781603278317
Ancien ou d'occasion
Couverture rigide
Vendeur : Research Ink, Takoma Park, MD, Etats-Unis
Évaluation du vendeur 4 sur 5 étoiles
Hardback. Etat : Very Good. xvii + 428 pp. Rubber-stamped on front free endpaper. book. N° de réf. du vendeur 26082
Quantité disponible : 1 disponible(s)
Image d'archives
Drug Management of Prostate Cancer
Edité par
Springer, 2010
ISBN 10 : 1603278311
ISBN 13 : 9781603278317
Ancien ou d'occasion
Couverture rigide
Vendeur : Phatpocket Limited, Waltham Abbey, HERTS, Royaume-Uni
Évaluation du vendeur 5 sur 5 étoiles
Etat : Good. Your purchase helps support Sri Lankan Children's Charity 'The Rainbow Centre'. Ex-library, so some stamps and wear, but in good overall condition. Our donations to The Rainbow Centre have helped provide an education and a safe haven to hundreds of children who live in appalling conditions. N° de réf. du vendeur Z1-U-005-01796
Quantité disponible : 1 disponible(s)
Image d'archives
Drug Management Of Prostate Cancer
Vendeur : Basi6 International, Irving, TX, Etats-Unis
Évaluation du vendeur 5 sur 5 étoiles
Etat : Brand New. New. US edition. Expediting shipping for all USA and Europe orders excluding PO Box. Excellent Customer Service. N° de réf. du vendeur ABEJUNE24-315410
Quantité disponible : 1 disponible(s)
Image d'archives
Drug Management of Prostate Cancer
Vendeur : ALLBOOKS1, Direk, SA, Australie
Évaluation du vendeur 5 sur 5 étoiles
N° de réf. du vendeur SHUB315410
Quantité disponible : 1 disponible(s)
Image d'archives
Drug Management of Prostate Cancer
Edité par
Springer New York, 2010
ISBN 10 : 1603278311
ISBN 13 : 9781603278317
Ancien ou d'occasion
Couverture rigide
Vendeur : Buchpark, Trebbin, Allemagne
Évaluation du vendeur 5 sur 5 étoiles
Etat : Sehr gut. Zustand: Sehr gut | Sprache: Englisch | Produktart: Bücher. N° de réf. du vendeur 5168239/12
Quantité disponible : 1 disponible(s)
Image fournie par le vendeur
Drug Management of Prostate Cancer
Edité par
Springer New York, 2010
ISBN 10 : 1603278311
ISBN 13 : 9781603278317
Neuf
Couverture rigide
Vendeur : moluna, Greven, Allemagne
Évaluation du vendeur 5 sur 5 étoiles
Etat : New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Provides a comprehensive guide to the spectrum of emerging pharmacologic agentsCovers both standard of care and investigational therapeuticsWritten by recognized international authorities in the fieldWell suited . N° de réf. du vendeur 4233635
Quantité disponible : Plus de 20 disponibles
Image fournie par le vendeur
Drug Management of Prostate Cancer
Edité par
Springer New York, Springer US Sep 2010, 2010
ISBN 10 : 1603278311
ISBN 13 : 9781603278317
Neuf
Couverture rigide
Vendeur : BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Allemagne
Évaluation du vendeur 5 sur 5 étoiles
Buch. Etat : Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Prostate cancer is the most common noncutaneous prostate cancer. Research has revealed several distinct malignancy and the second leading cause of cancer mechanisms of castration-resistant disease that may deaths among men in the United States. It is a critical converge in patients with disease progression on public health problem and remains incurable in the ADT. Many approaches are currently being evaluated metastatic setting with mortality that usually occurs as to improve the treatment of this condition and these a result of castration-resistant disease. fndings have identifed several potential targets for Since Huggins and Hodges' report of the dra- therapeutic intervention. These include drugs that are matic clinical effects of suppressing serum testos- more active or less toxic chemotherapy agents; drugs terone levels in men with advanced prostate cancer that induce androgen deprivation; drugs that target in 1941, hormone therapy (also called androgen the androgen receptor and/or androgen synthesis; deprivation therapy [ADT]) has become widely drugs that target specifc pathways, including ang- accepted as the mainstay of therapy for the treat- genesis and tyrosine kinase inhibitors, endothelin ment of advanced prostate cancer. ADT combined antagonists and matrix metalloproteinase inhibitors; with radiation therapy is a standard of care in the and immunologic approaches. Many of these agents treatment of men with locally advanced prostate seem promising and the rationale and effcacy of cancer on the basis of evidence that shows improved these emerging therapies remain to be validated in survival. The role of ADT in the management of future clinical trials. 448 pp. Englisch. N° de réf. du vendeur 9781603278317
Quantité disponible : 2 disponible(s)
Image d'archives
Drug Management of Prostate Cancer
Vendeur : Books Puddle, New York, NY, Etats-Unis
Évaluation du vendeur 4 sur 5 étoiles
Etat : New. pp. 698 1st Edition. N° de réf. du vendeur 261985795
Quantité disponible : 4 disponible(s)
Image fournie par le vendeur
Drug Management of Prostate Cancer
Edité par
Springer New York, Springer US Sep 2010, 2010
ISBN 10 : 1603278311
ISBN 13 : 9781603278317
Neuf
Couverture rigide
Vendeur : buchversandmimpf2000, Emtmannsberg, BAYE, Allemagne
Évaluation du vendeur 5 sur 5 étoiles
Buch. Etat : Neu. Neuware -Prostate cancer is the most common noncutaneous prostate cancer. Research has revealed several distinct malignancy and the second leading cause of cancer mechanisms of castration-resistant disease that may deaths among men in the United States. It is a critical converge in patients with disease progression on public health problem and remains incurable in the ADT. Many approaches are currently being evaluated metastatic setting with mortality that usually occurs as to improve the treatment of this condition and these a result of castration-resistant disease. fndings have identifed several potential targets for Since Huggins and Hodges¿ report of the dra- therapeutic intervention. These include drugs that are matic clinical effects of suppressing serum testos- more active or less toxic chemotherapy agents; drugs terone levels in men with advanced prostate cancer that induce androgen deprivation; drugs that target in 1941, hormone therapy (also called androgen the androgen receptor and/or androgen synthesis; deprivation therapy [ADT]) has become widely drugs that target specifc pathways, including ang- accepted as the mainstay of therapy for the treat- genesis and tyrosine kinase inhibitors, endothelin ment of advanced prostate cancer. ADT combined antagonists and matrix metalloproteinase inhibitors; with radiation therapy is a standard of care in the and immunologic approaches. Many of these agents treatment of men with locally advanced prostate seem promising and the rationale and effcacy of cancer on the basis of evidence that shows improved these emerging therapies remain to be validated in survival. The role of ADT in the management of future clinical trials.Humana Press in Springer Science + Business Media, Heidelberger Platz 3, 14197 Berlin 448 pp. Englisch. N° de réf. du vendeur 9781603278317
Quantité disponible : 2 disponible(s)
Image d'archives
Drug Management of Prostate Cancer
impression à la demandeVendeur : Majestic Books, Hounslow, Royaume-Uni
Évaluation du vendeur 5 sur 5 étoiles
Etat : New. Print on Demand pp. 698. N° de réf. du vendeur 6943452
Quantité disponible : 4 disponible(s)